About this trial

Some of the patients affected by Out-of-hospital cardiac arrest (OHCA) with ventricular fibrillation (VF)/ventricular tachycardia (VT) do not respond to initial defibrillation. The survival decreases with number of defibrillations required to terminate VF/VT. In 2022, one prospective cluster randomized trial showed increased survival among (OHCA) patients in refractory VF using Double Sequential Defibrillation (DSD). If DSD can increase survival among all patients in VF that dont respond to one defibrillation, i.e. before it has become refractory is not known.

The aim of this trial is to assess survival with a double defibrillation strategy initiated as soon as possible among patients with Out of Hospital Cardiac Arrest with initial shockable rhythm and at least one failed standard defibrillation, compared with continued resuscitation using standard defibrillation.

Eligibility criteria

Qualifiers

OHCA patients with VT/VF at first rhythm analysis and at least one defibrillation performed in standard (A-L) position

Disqualifiers

Age < 18 years

Obvious pregnancy

Known preexisting Do Not Attempt Resuscitation order

Trial design

Treatments tested in this trial

  • Double sequential defibirllation
  • Standard defibrillation

Treatment groups

916 Participants
are divided into 2 treatment groups

Locations

14
Netherlands
ARREST (AmsteRdam REsuscitation STudies) Amsterdam Netherlands
Spain
Centro de Emergencias 061 Andalucía29560, MálagaAndalusia, Spain
Médico Emergencias Osakidetza EMERGENTZIAK48004, BilbaoBaque Country, Spain
Sistema de Emergencias Medicas de Catalunya08908, BarcelonaCatalonia, Spain

Sponsors and collaborators

Gabriel Riva

Lead sponsor

Karolinska Institutet

Sponsor institution

Swedish Heart Lung Foundation

Collaborator

Region Stockholm

Collaborator

Vastra Gotaland Region

Collaborator

Region Halland

Collaborator

Laerdal Foundation

Collaborator